Engineered immune cells take on liver cancer in early trial

NCT ID NCT07487402

Not yet recruiting Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial will test a new type of cell therapy called Meta10-GPC3 CAR-T in 27 people with advanced liver cancer that cannot be surgically removed. The treatment involves taking a patient's own immune cells, modifying them to recognize and attack liver cancer cells, and giving them back by infusion. The main goal is to check safety, but researchers will also look for signs that the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Meta10-GPC3 CAR-T cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for advanced liver cancer that has not responded to other therapies.
What could go wrong: This is a very early, small trial (27 people) focused on safety, so it is unknown if the treatment will shrink tumors or improve survival. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

The first affiliated hospital of medical college of zhejiang university

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.